Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.

Disclosure: The author does not hold a position in CRSP.

← Back to Free Index

CRSP

Analysis as of: 2026-10-14

CRISPR Therapeutics AG

CRISPR Therapeutics develops gene-edited medicines and cell therapies, shares economics from the first approved CRISPR-based therapy with Vertex, and is advancing wholly owned cardiometabolic, autoimmune, oncology, and anticoagulation programs.

biotech healthcare

On Yahoo Finance ...

Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Validated editing, but the next proof points matter

A first approved gene-editing product and deep liquidity give this platform real staying power. The upside now depends on whether cardiometabolic and autoimmune programs convert scientific credibility into wholly owned, scalable economics.

Analysis

Thesis

CRISPR Therapeutics already has first-product credibility and enough capital to fund multiple shots on goal; if pediatric access expands the launch and one wholly owned cardiometabolic or autoimmune asset becomes clearly late-stage worthy by 2031, the company can re-rate from cash-rich science platform to a multi-franchise gene-editing business.

Last Economy Alignment

AI should help target design, trial prioritization, and portfolio learning, while value capture stays anchored in IP, clinical data, manufacturing, and regulatory trust rather than easily copied software. The limiter is that biology, reimbursement, and site activation still scale much slower than code.

Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple

2.5x (from 5 most recent analyses)

Reasoning

The upside case does not need every program to work. A steadier commercial base from the first approved therapy, plus one meaningful wholly owned franchise in cardiometabolic disease or autoimmune cell therapy, is enough to justify a materially larger business. The cap on upside is that access, shared economics, and early-stage proof burden still slow value realization, so this looks like strong but not extreme compounding.

Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary

The main risk is proof conversion, not survival. The balance sheet buys time, but the stock still needs faster commercial cash flow from the first approved therapy and at least one clean wholly owned win in cardiometabolic or autoimmune disease. If those gates slip, valuation can stall around cash plus scientific optionality rather than compound as a durable franchise.

Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Trends

Key Changes

On October 8, 2026, management set the Phase 1b cardiometabolic readout for November 9, 2026 at AHA, tightening timing around the most important near-term value gate.
On October 2, 2026, management set the autoimmune cell-therapy poster for November 8, 2026 at ACR, clarifying timing for the second key proof point.
No new financing, safety warning, or commercial setback was disclosed in the last 7-10 days; the change is better catalyst visibility, not new efficacy evidence.

Upgrade to Builder to also access: Future Considerations

Last Economy Structure

AI Industrial Score

0.33

They own gene-editing know-how, clinical data, and some manufacturing control, so AI should help them design better medicines faster without turning the product into a commodity. The hard bottlenecks are still approvals, treatment-site access, and proving the next programs work.

Upgrade to Reader to also access: Score Decomposition, Confidence Level

Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility

Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target

$87.56

Upgrade to Reader to also access: Bull Case, Base Case, Bear Case

Next Arc Research